Rheumatoid Arthritis: What It Is, How It Affects the Body, and the Role of Manual Therapy

What Is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease characterised by synovial joint inflammation, progressive articular destruction, and wide-ranging extra-articular manifestations. Unlike osteoarthritis — which is primarily a degenerative condition driven by mechanical wear — RA is driven by dysregulated immune activity. The synovium, the membrane lining synovial joints, becomes the primary target: immune cells infiltrate the synovial tissue, producing a thickened, hyperplastic lining called a pannus that releases proteolytic enzymes, cytokines, and matrix metalloproteinases capable of eroding cartilage and subchondral bone. The result, without appropriate treatment, is progressive joint destruction, deformity, and disability. RA affects approximately 1% of the global population and is two to three times more common in women than men, with peak onset between the fourth and sixth decades of life.

The Inflammatory Mechanism

The immunopathology of RA involves both innate and adaptive immune dysfunction. T-helper cells (particularly Th17 cells), B cells, macrophages, and mast cells all participate in perpetuating synovial inflammation. Key inflammatory mediators include tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1 (IL-1), and receptor activator of nuclear factor kappa-B ligand (RANKL) — the latter stimulating osteoclast activity and driving periarticular bone erosion. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies — present in the majority of seropositive RA patients — are produced by activated B cells and contribute to immune complex deposition in the synovium. Anti-CCP antibodies are particularly specific to RA and may be detectable years before clinical symptoms emerge, representing a potential early diagnostic marker.

Clinical Presentation

RA classically presents with symmetrical, polyarticular joint involvement — affecting the same joints on both sides of the body, typically the small joints of the hands (MCP and PIP joints), wrists, feet (MTP joints), and ankles first, with larger joints involved as the disease progresses. The hallmark features include morning stiffness lasting more than an hour (a reliable indicator of inflammatory rather than degenerative joint disease), joint swelling, warmth, and pain. Systemic symptoms — fatigue, low-grade fever, weight loss — are common, reflecting the systemic inflammatory burden. Extra-articular manifestations include rheumatoid nodules (subcutaneous nodules over bony prominences), pulmonary involvement (interstitial lung disease), vasculitis, Sjögren's syndrome overlap, and an increased cardiovascular risk that makes early aggressive disease control imperative.

Medical Management

Medical management of RA has been transformed over the past three decades. The cornerstone of treatment is disease-modifying antirheumatic drugs (DMARDs) — medications that alter the underlying disease course rather than merely controlling symptoms. Methotrexate remains the first-line anchor DMARD, often combined with hydroxychloroquine and sulfasalazine (triple therapy). For patients with inadequate response to conventional DMARDs, biologic agents targeting specific inflammatory mediators — TNF-α inhibitors (e.g. adalimumab, etanercept), IL-6 receptor antagonists (e.g. tocilizumab), and B cell depleters (rituximab) — have dramatically improved outcomes. The treat-to-target strategy, aiming for remission or low disease activity as measured by validated indices, has replaced symptom management as the therapeutic goal and has substantially reduced long-term joint destruction and disability.

The Role of Manual Therapy and Exercise

Manual therapy, myotherapy, and structured exercise are important adjuncts to medical management in RA — not alternatives to it. The evidence supports their role in reducing pain, improving joint range of motion, maintaining muscle strength, and enhancing quality of life. During active flares, gentle range-of-motion work, hydrotherapy, and pain-modulating techniques are appropriate. During remission, progressive resistance training is strongly supported: it counteracts the muscle wasting (sarcopenia) and periarticular weakness common in RA, improves functional capacity, and — contrary to historical misconception — does not aggravate joint inflammation. Aerobic exercise improves cardiovascular risk profile. Myofascial release and soft tissue work addresses the secondary muscular guarding, altered movement patterns, and fatigue that accompany chronic inflammation. The clinician must always be aware of cervical spine involvement — atlanto-axial instability is a rare but serious complication of RA that requires caution with cervical manipulation.

Living Well with Rheumatoid Arthritis

Early, aggressive treatment of RA — guided by a rheumatologist — substantially reduces the risk of progressive joint damage and disability. Patients who achieve sustained remission on appropriate DMARDs can live full, active lives. Lifestyle factors matter: smoking significantly worsens RA prognosis and reduces DMARD efficacy; a Mediterranean dietary pattern reduces inflammatory burden; sleep hygiene and stress management influence disease activity. Regular review of both disease activity and treatment response enables timely adjustment of the medical regimen. A multidisciplinary team — rheumatologist, general practitioner, physiotherapist or myotherapist, occupational therapist, and podiatrist — provides the most comprehensive support across the dimensions of this complex condition.